- Conditions
- Sarcoma
- Interventions
- bevacizumab, doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 9,813
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine, Nab-paclitaxel, Ficlatuzumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Selected Advanced Solid Tumors
- Interventions
- EOS006215, Anticancer agent
- Drug
- Lead sponsor
- iTeos Belgium SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Sarasota, Florida
- Conditions
- Advanced Solid Tumor
- Interventions
- SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Canakinumab, Durvalumab, Radiation therapy, Chemotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
- Interventions
- COM701, COM701 with Opdivo (Nivolumab).
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced Solid Tumors, Lymphoid Malignancies
- Interventions
- Bardoxolone methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
- Conditions
- Solid Tumor
- Interventions
- BDTX-189
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Avelumab, Talazoparib, Talazoparib Tosylate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 325
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
- Conditions
- Mesothelioma, Mesothelioma; Lung, Mesotheliomas Pleural, Mesothelioma Malignant Advanced, Mesothelioma, Malignant
- Interventions
- Partial Pleurectomy
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Epithelial Cancer
- Interventions
- SPL-108
- Drug
- Lead sponsor
- Splash Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Head and Neck Cancer, Head Cancer, Neck Cancer
- Interventions
- RiMO-301, Pembrolizumab, Radiation, Surgical resection
- Drug · Radiation · Procedure
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Cancers
- Interventions
- Erlotinib Hydrochloride (Tarceva)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Radiation Therapy, Tremelimumab, Durvalumab, Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- OSE2101, Docetaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- OSE Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
- Conditions
- Oral Mucositis
- Interventions
- RRx-001, Cisplatin for injection, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
- Interventions
- nab-sirolimus
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
- Conditions
- Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
- Interventions
- Zalypsis
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Memphis, Tennessee • Seattle, Washington
- Conditions
- Advanced Solid Tumor
- Interventions
- AGEN1223, AGEN1223 and balstilimab
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 1 more
- Conditions
- Solid Tumors
- Interventions
- Iso-Fludelone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
- Interventions
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Months to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- ABI-011
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Interventions
- tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 124
- States / cities
- Encinitas, California • La Jolla, California • Sacramento, California + 57 more